| scholarly article | Q13442814 |
| P50 | author | Onur Başer | Q102872694 |
| P2093 | author name string | Li Wang | |
| Lin Xie | |||
| Wenhui Wei | |||
| Raymond Miao | |||
| P2860 | cites work | Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). | Q22241288 |
| Meta-analysis of individual patient data to assess the risk of hypoglycaemia in people with type 2 diabetes using NPH insulin or insulin glargine | Q33637807 | ||
| NIH disease funding levels and burden of disease | Q33839499 | ||
| Insulin glargine in the management of diabetes mellitus: an evidence-based assessment of its clinical efficacy and economic value. | Q34449820 | ||
| Does medication adherence lower Medicare spending among beneficiaries with diabetes? | Q35089645 | ||
| Impact of hypoglycemia associated with antihyperglycemic medications on vascular risks in veterans with type 2 diabetes | Q35898351 | ||
| Making the transition from oral to insulin therapy | Q36105625 | ||
| Basal supplementation of insulin lispro protamine suspension versus insulin glargine and detemir for type 2 diabetes: meta-analysis of randomized controlled trials | Q36426817 | ||
| A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes | Q36449523 | ||
| Insulin analogs: impact on treatment success, satisfaction, quality of life, and adherence | Q36947990 | ||
| Economic costs of diabetes in the U.S. In 2007. | Q37097601 | ||
| Persistence with injectable antidiabetic agents in members with type 2 diabetes in a commercial managed care organization | Q37634499 | ||
| Influence of Intensive versus Conventional Glucose Control on Microvascular and Macrovascular Complications in Type 1 and 2 Diabetes Mellitus | Q37809843 | ||
| A review of diabetes treatment adherence and the association with clinical and economic outcomes | Q37852413 | ||
| Humalog (lispro) for type 2 diabetes | Q38050151 | ||
| Indirect cost burden of migraine in the United States | Q38463013 | ||
| Cost-effectiveness of insulin glargine versus NPH insulin for the treatment of Type 2 diabetes mellitus, modeling the interaction between hypoglycemia and glycemic control in Switzerland. | Q39781917 | ||
| Health, absence, disability, and presenteeism cost estimates of certain physical and mental health conditions affecting U.S. employers | Q40518259 | ||
| Cost sharing, adherence, and health outcomes in patients with diabetes | Q42672185 | ||
| Direct costs associated with initiating NPH insulin versus glargine in patients with type 2 diabetes: a retrospective database analysis | Q43630429 | ||
| Productivity costs associated with cardiometabolic risk factor clusters in the United States | Q43865518 | ||
| A real-world study of patients with type 2 diabetes initiating basal insulins via disposable pens | Q44235147 | ||
| Assessment of adherence and healthcare costs of insulin device (FlexPen) versus conventional vial/syringe | Q45343958 | ||
| Resource utilisation and costs in patients with type 2 diabetes mellitus treated with insulin glargine or conventional basal insulin under real-world conditions in Germany: LIVE-SPP study. | Q46007489 | ||
| Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes | Q46406475 | ||
| Economic and humanistic outcomes associated with comorbid type-2 diabetes, high cholesterol, and hypertension among individuals who are overweight or obese | Q46602748 | ||
| Multidimensional analysis of treatment adherence in patients with multiple chronic conditions. A cross-sectional study in a tertiary hospital | Q46890302 | ||
| Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven Phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellit | Q46963862 | ||
| Does pen help? A real-world outcomes study of switching from vial to disposable pen among insulin glargine-treated patients with type 2 diabetes mellitus | Q50540970 | ||
| Major complications have an impact on total annual medical cost of diabetes: results of a database analysis. | Q50780689 | ||
| Burden of illness in painful diabetic peripheral neuropathy: the patients' perspectives | Q50916339 | ||
| The effect of obesity and cardiometabolic risk factors on expenditures and productivity in the United States | Q51127959 | ||
| Labour productivity effects of prescribed medicines for chronically ill workers | Q71558224 | ||
| Twenty-four hour action of insulin glargine (Lantus) may be too short for once-daily dosing: a case report | Q74530226 | ||
| Burden of hospitalizations primarily due to uncontrolled diabetes: implications of inadequate primary health care in the United States | Q79750542 | ||
| Modelling cost effectiveness of insulin glargine for the treatment of type 1 and 2 diabetes in Canada | Q79865927 | ||
| Cost-effectiveness and cost-utility of insulin glargine compared with NPH insulin based on a 10-year simulation of long-term complications with the Diabetes Mellitus Model in patients with type 2 diabetes in Switzerland | Q80253601 | ||
| Occupational injuries among workers with diabetes: the National Health Interview Survey, 1997-2005 | Q81618464 | ||
| Impact of medication adherence on hospitalization risk and healthcare cost | Q81772147 | ||
| The association of two productivity measures with health risks and medical conditions in an Australian employee population | Q83360239 | ||
| Two-year glycaemic control and healthcare expenditures following initiation of insulin glargine versus neutral protamine Hagedorn insulin in type 2 diabetes | Q83630346 | ||
| Clinical impact of initiating insulin glargine therapy with disposable pen versus vial in patients with type 2 diabetes mellitus in a managed care setting | Q84061339 | ||
| Direct health care costs of patients with type 2 diabetes within a privately insured employed population, 2000 and 2005 | Q84969435 | ||
| P433 | issue | 4 | |
| P921 | main subject | insulin glargine | Q417317 |
| type 2 diabetes | Q3025883 | ||
| preproinsulin | Q7240673 | ||
| P577 | publication date | 2013-04-30 | |
| P1433 | published in | BMJ Open | Q17003470 |
| P1476 | title | Real-world outcomes of US employees with type 2 diabetes mellitus treated with insulin glargine or neutral protamine Hagedorn insulin: a comparative retrospective database study | |
| P478 | volume | 3 |
| Q90537112 | A comparative effectiveness study of degludec and insulin glargine 300 U/mL in insulin-naïve patients with type 2 diabetes |
| Q92060576 | Basal Insulin Initiation and Maintenance in Adults with Type 2 Diabetes Mellitus in the United States |
| Q37639294 | Basal Insulin Persistence, Associated Factors, and Outcomes After Treatment Initiation: A Retrospective Database Study Among People with Type 2 Diabetes Mellitus in Japan |
| Q53592593 | Basal insulin initiation use and experience among people with type 2 diabetes mellitus with different patterns of persistence: results from a multi-national survey. |
| Q33884347 | Cost of medication adherence and persistence in type 2 diabetes mellitus: a literature review |
| Q36120727 | Diabetes care among elderly medicare beneficiaries with Parkinson's disease and diabetes |
| Q33707304 | Distinguishing Selection Bias and Confounding Bias in Comparative Effectiveness Research |
| Q36159019 | Early discontinuation and related treatment costs after initiation of Basal insulin in type 2 diabetes patients: a German primary care database analysis |
| Q37699685 | Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) Therapy Adherence for Patients with Type 2 Diabetes in a Medicare Population |
| Q91755046 | Injectable Antihyperglycemics: A Systematic Review and Critical Analysis of the Literature on Adherence, Persistence, and Health Outcomes |
| Q37650091 | Insulin adherence and persistence among Chinese patients with type 2 diabetes: a retrospective database analysis |
| Q53598738 | Insulins NPH, glargine, and detemir, and risk of severe hypoglycemia among working-age adults. |
| Q38901991 | Lixisenatide as add-on treatment among patients with different β-cell function levels as assessed by HOMA-β index |
| Q37239307 | Persistence with Insulin Therapy in Patients with Type 2 Diabetes in France: An Insurance Claims Study. |
| Q47248324 | Relationship between treatment persistence and A1C trends among patients with type 2 diabetes newly initiated on basal insulin. |
| Q35048157 | Resource use and outcomes associated with initiation of injectable therapies for patients with type 2 diabetes mellitus |
| Q35217922 | Starting insulin in type 2 diabetes: real-world outcomes after the first 12 months of insulin therapy in a new zealand cohort |
| Q48088343 | Switching basal insulins in type 2 diabetes: practical recommendations for health care providers |
| Q26999454 | The evolution of insulin glargine and its continuing contribution to diabetes care |
Search more.